17 min listen
CRISPR, Gene Therapies, and Cure Pricing Conundrums
CRISPR, Gene Therapies, and Cure Pricing Conundrums
ratings:
Length:
24 minutes
Released:
Sep 17, 2022
Format:
Podcast episode
Description
Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the possibilities for CRISPR, from sickle cell cures to drought-resistant crops - How investors can approach investing in gene therapies - Biotech metrics to watch. Companies mentioned: BLUE, CRSP, GILD, EDIT, VRTX, NTLA Host: Ricky Mulvey Guest: Karl Theil Engineers: Tim Sparks, Dan Boyd
Released:
Sep 17, 2022
Format:
Podcast episode
Titles in the series (100)
Motley Fool Money: 04.09.2009: Wells Fargo banks big profits. Amazon.com and Apple face the music. The SEC considers hemming some shorts. And Segway and GM introduce their pet PUMA. On this week’s Motley Fool Money, we tackle those topics, offer a few stock ideas, share a few... by Motley Fool Money